http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Jia-Horng Lin,Lu Yang,Xianjin Hu,Haokai Peng,Haitao Ren,Ting-Ting Li,Ching-Wen Lou 한국공업화학회 2023 Journal of Industrial and Engineering Chemistry Vol.128 No.-
Bacterial infection is one of the major threats to human health worldwide, posing a great challenge to thedevelopment of medical protective materials with efficient filtration and long-lasting antimicrobial properties. In this study, electrospinning technology and non-woven fabrics were combined to construct amicro/nano-structured photodynamic rechargeable and storable antibacterial filtration composite membrane. The filtration efficiency of the composite membrane is as high as 99.99% for 0.5–5 lm particles,and the resistance pressure drop is 85 Pa. In addition, the release of OH and H2O2 from the compositefilm reached 5326.16 lg/g and 711.93 lg/g, respectively. After 7 cycles of quenching, the charging capacityretains more than 70 % of the original. It showed good antimicrobial properties even when storedunder dark conditions for one month. The bactericidal efficiency of the composite membrane againstE. coli and S. aureus exceeded 99% under both dark and light conditions. The development of this simpleand clean micro/nanofiber membrane provides a new idea for exploring photoactive antimicrobial andfiltration materials for medical protection.
Ashok Thorat,Long-Bin Jeng,Horng-Ren Yang,Chun-Chieh Yeh,Shih-Chao Hsu,Te-Hung Chen,Kin-Shing Poon 한국간담췌외과학회 2017 Annals of hepato-biliary-pancreatic surgery Vol.21 No.4
Backgrounds/Aims: The protective effect of everolimus (EVR) in hepatocellular carcinoma (HCC) patients who receive liver transplantation in terms of reducing the recurrence has not been sufficiently investigated in clinical trials. In this second stage of our ongoing study, we intend to analyze the effects of EVR as an immunosuppressant, when it is started in the early phase after living donor liver transplantation (LDLT), on HCC recurrence in patients with HCC within the University of California at San Francisco (UCSF) criteria. Methods: From January 2011 to June 2013, a total of 250 patients underwent LDLT for HCC at our institute. The patients with HCC within the UCSF criteria were included in the study and divided in two groups depending upon the postoperative immunosuppression. Group A: HCC patients that received EVR+TAC based immunosuppressive regimen (n=37). Group B: HCC patients that received standard TAC based immunosuppressive regimen without EVR (n=29). The target trough level for EVR was 3 to 5 ng/ml while for TAC it was 8-10 ng/ml. Results: For group A patients, the mean trough level of the EVR was 3.47±1.53 ng/ml (range, 1.5-11.2) with a daily dose of 1.00±0.25 mg/day. For group A and B, the average TAC trough levels were 6.97±3.98 ng/ml (range, 2.50 to 11.28 ng/ml) and 6.93±2.58 (range, 2-16.30), respectively. The 1-year, 3-year and 4-year overall survival achieved for Group A patients was 94.95%, 86.48% and 86.48%, respectively while for Group B patients it was 82.75%,68.96%, and 62.06%, respectively (p=0.0217). Conclusions: EVR use in liver transplant recipients in the early stage after transplantation reduces the HCC recurrence rates in HCC patients within the UCSF criteria.